Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 18,748 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm
Interventions: Alisertib, Pembrolizumab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Geographic Atrophy
Interventions: NGM621; Biological
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Arcadia, California • Newport Beach, California • Melbourne, Florida + 3 more

Conditions: Hepatic Impairment
Interventions: Alpelisib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Lakewood, Colorado • Miami, Florida • Orlando, Florida + 1 more

Conditions: Dermatitis, Atopic
Interventions: P3-Fast, Comm-Fast, Vari-Fast, Comm-Fed; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: TG02 citrate; Drug
Lead sponsor: Tragara Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Augusta, Georgia • Boston, Massachusetts • Columbus, Ohio + 2 more

Conditions: Pancreatic Cancer
Interventions: gemcitabine hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: BIIB104 Reference Formulation, BIIB104 Test Formulation; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Advanced Solid Tumor
Interventions: SLC-3010, Gemcitabine; Drug · Combination Product
Lead sponsor: Selecxine; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Sarasota, Florida • Detroit, Michigan • Oklahoma City, Oklahoma

Conditions: Renal Impairment
Interventions: CTP-543; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Neoplasms, Pituitary Neoplasms
Interventions: OTL38; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatic Impairment
Interventions: Enasidenib; Drug
Lead sponsor: Celgene; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more

Conditions: Refractory TdT-Positive Leukemia
Interventions: Cordycepin plus Pentostatin; Drug
Lead sponsor: OncoVista, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Boston, Massachusetts • San Antonio, Texas

Conditions: Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer, Other Solid Tumors
Interventions: HC-5404-FU; Drug
Lead sponsor: HiberCell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Detroit, Michigan • Saint Paul, Minnesota • Dallas, Texas + 1 more

Conditions: Pancreatic Cancer
Interventions: fluorouracil, leucovorin calcium, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Myeloma, Plasma Cell Disorder
Interventions: HDP-101; Drug
Lead sponsor: Heidelberg Pharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Omaha, Nebraska + 2 more

Conditions: Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers
Interventions: Solifenacin Succinate Formulation A, Solifenacin Succinate Formulation B, Solifenacin Succinate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Neoplasms, Lymphoma
Interventions: LMP400, LMP776; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chemotherapy-induced Neutropenia
Interventions: EC-18, Placebo; Drug
Lead sponsor: Enzychem Lifesciences Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Cystic Fibrosis
Interventions: VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 12
States / cities: Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more

Conditions: Glioblastoma
Interventions: Vorinostat, Bevacizumab, Irinotecan; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Marijuana Abuse
Interventions: AEF0117; Drug
Lead sponsor: Aelis Farma; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: [14C]-LY3866288, LY3866288; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Fistula Vagina, Crohn Disease
Interventions: MSC-AFP; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: PF-06826647, Oral Contraceptive (OC); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Coral Gables, Florida • Miami, Florida

Search by objective public record fields.

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

Study of NGM621 in Participants With Geographic Atrophy

Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.

Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer

A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

Intraoperative Imaging of Pituitary Adenomas by OTL

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia

A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation

A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas

A Safety and PK Study of EC-18 in Healthy Subjects

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects

A Study of [14C]-LY3866288 in Healthy Participants

Stem Cell Coated Fistula Plug in Patients With Crohn's RVF

A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants